Clinical Trial Search

Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…

Primary: Prevalence of HIV Infection — 6 Participants

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1

Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244

Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio

Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants

Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL

Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants

Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants

Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…

Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants

Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005

Primary: Change on Malondialdehyde After Treatment With Omega 3 Acids for 6 Months Compared With Placebo in HIV Seropositive Patients — -1.18; -0.9 nM/mg protein

Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants

Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens

Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133

Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive

Primary: Accessibility of Testing Results — 0.642; 0.981 proportion of participants — p=<0.001

Primary: Feasibility - Session Attendance — 5; 5 Participants